Related Experiment Video
Updated: Apr 20, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
[Therapy of intermediate uveitis]
D Doycheva1, C Deuter, M Zierhut
1Universitäts-Augenklinik Tübingen, Schleichstr. 12-16, 72076, Tübingen, Deutschland, deshka.doycheva@med.uni-tuebingen.de.
Intermediate uveitis, an eye inflammation primarily affecting the vitreous, is typically managed with systemic corticosteroids. Immunosuppressive drugs or biologics are used for resistant cases or side effects.
Area of Science:
- Ophthalmology
- Immunology
Context:
- Intermediate uveitis involves inflammation within the eye, specifically targeting the vitreous.
- Systemic corticosteroids are the primary medical treatment for this condition.
Purpose:
- To outline the therapeutic strategies for intermediate uveitis.
- To discuss alternative treatments when initial therapy fails or causes side effects.
Summary:
- Corticosteroids are the mainstay for intermediate uveitis, but immunosuppressive agents like Cyclosporine A are crucial for managing recurrences or adverse effects.
- For severe, refractory cases, biologics offer a treatment option.
- Intravitreal steroids or vitrectomy may be considered in specific situations, such as unilateral disease or contraindications to systemic therapy.
Impact:
- Provides a comprehensive overview of intermediate uveitis management.
- Highlights the role of various immunosuppressive and biologic therapies in optimizing patient outcomes.
- Informs clinical decision-making for complex cases of intermediate uveitis.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Pericarditis III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myocarditis III: Medical Management

